Search Bar & Filters
Found 29 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.
Actively Recruiting
Healthy Volunteer
Carpal Tunnel Syndrome is a common condition that causes symptoms like tingling, pain, numbness, and weakness. Surgery called carpal tunnel release is the most effective treatment. This research compares two types of sutures used to close wounds after surgery absorbable and non-absorbable to see if one type affects the chance of wound infection. The study is a randomized controlled trial investigating how sutures influence infections after surgery. Participants will receive carpal tunnel release surgery where the flexor retinaculum is cut to relieve pressure. After surgery, wounds will be closed using either absorbable sutures Vicryl rapide or Safil quick or non-absorbable sutures Ethilon or Flexocrin. Both suture types are commonly used, but this study aims to find if one leads to fewer infections. The trial does not use masking, and participants are randomly assigned to one of the two suture groups. During the study, researchers will assess wound healing using the ASEPSIS wound score between 10 and 14 days after surgery. Patients will also record their pain using a Numeric Rating Scale for up to three weeks after surgery. Use of antibiotics, hand therapy, and any extra doctor visits will be recorded. The study is sponsored by Gelre Hospitals and includes adult participants aged 18 and older. Participation may last several weeks for follow-up and assessments.
Actively Recruiting
This research aims to evaluate whether preventive endovascular stenting of a significant narrowing over 50% in the superior mesenteric artery SMA can reduce the risk of anastomotic leakage AL after elective colon surgery. AL is a serious complication linked to higher mortality, lower quality of life, and increased healthcare costs. A prior study showed that having more than 50% SMA stenosis raises the risk of AL sixfold, and this trial investigates if stenting this artery before surgery can help prevent AL. Participants are randomly assigned to one of two groups the intervention group will receive preventive angioplasty and placement of a covered stent in the SMA before their colon surgery, while the control group will proceed with colon surgery without stenting. Both groups receive daily mono antiplatelet therapy with carbasalate calcium, lifelong for the intervention group and at least 12 months for the control group. The stenting procedure is minimally invasive and performed preferably within two weeks before surgery at specialized centers. Colon surgery is done according to standard local guidelines. Some centers will use intraoperative fluorescence angiography to assess blood flow during surgery. During the 12 months of follow-up after surgery, participants will be monitored for anastomotic leakage within the first 90 days, as well as delayed leakage and surgical complications up to one year. Researchers will collect data on hospital stays, reinterventions, mortality, quality of life, healthcare costs, and stent function. Patient-reported outcomes will be gathered through questionnaires at multiple time points. The study also includes imaging assessments and cost-effectiveness analyses to understand the broader impact of preventive stenting.
Actively Recruiting
Adhesions are common after abdominal surgery and can cause serious problems like chronic pain, bowel obstruction, or complications during repeat surgeries. Researchers are studying how well functional cine magnetic resonance imaging MRI can detect and map these adhesions in patients who have had previous abdominal surgery. This observational study aims to determine the accuracy of cineMRI in identifying adhesions to the abdominal wall and between organs. Participants will undergo a cineMRI scan of the abdomen using a 1.5 Tesla MRI machine. The study will observe patients who have a history of laparotomy with a median abdominal scar of at least 10 cm. There are no treatment interventions the focus is on imaging and diagnostic evaluation. During the study, participants will be assessed by comparing cineMRI results with surgical findings to measure the sensitivity and specificity of the MRI in detecting adhesions. The primary outcome is evaluated within two weeks. The study is conducted at multiple centers and is sponsored by Radboud University Medical Center.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are investigating whether taking breaks from the standard combination therapy of daratumumab, lenalidomide, and dexamethasone Dara-Rd for newly diagnosed multiple myeloma patients affects survival and quality of life. This study aims to compare continuous treatment versus planned treatment-free intervals to see if stopping therapy temporarily may reduce side effects, allow recovery from toxicity, and improve overall well-being while controlling the disease. Participants who have completed 12 cycles of Dara-Rd with at least a partial response and no signs of disease progression will be randomly assigned to one of two groups. One group will continue Dara-Rd therapy without interruption until disease progression, while the other group will stop treatment temporarily and restart it at biochemical progression, continuing until disease progression. The trial is open-label and will follow patients for several years to assess outcomes. Throughout the study, researchers will monitor participants event-free survival and progression-free survival for up to about 57 and 69 months, respectively. Additional assessments include side effect burden, patient-reported quality of life, treatment costs, treatment-free interval length, response times, and survival after second-line therapy. Regular evaluations will help determine how treatment interruption affects toxicity, dose intensity, and overall treatment outcomes over the long term.
Actively Recruiting
This research focuses on patients with acute coronary syndrome ACS, a leading cause of death worldwide. It aims to create an ongoing registry to evaluate the long-term effects of diagnostics, treatments, and devices used for ACS in real-world clinical practice. The study addresses gaps left by traditional randomized controlled trials by capturing data from routine care and broader patient populations to improve cardiovascular care and quality of life. The study uses a nonrandomized observational design to collect detailed clinical and possibly genetic information from patients with ACS. This registry allows evaluation of various therapies, devices, and diagnostic tools used in daily practice. It also examines follow-up care pathways, risk score usage for medication duration, and adherence to treatment guidelines, aiming to enhance personalized medicine and secondary prevention. Participants provide information during routine clinical visits, with data collected prospectively and followed over time. Researchers monitor outcomes such as mortality, recurrent ischemic events, hospital admissions, and quality of life. The main measure is the number of participants tracked at three years. This long-term observation helps evaluate the effectiveness and safety of treatments in everyday clinical settings and supports ongoing improvements in ACS care.
Actively Recruiting
Researchers are investigating healthcare use patterns in patients with liver cirrhosis, including those with compensated and decompensated disease. This multicenter, retrospective cohort study aims to understand the disease course and factors like psychosocial aspects that may influence healthcare utilization. The study is observational and sponsored by Maastricht University Medical Center. Participants do not receive any intervention as this study collects and analyzes existing healthcare data. The focus is on reviewing past outpatient visits, radiographic imaging, esophagogastroscopies, and elastographies related to liver cirrhosis within the two years before complications, death, or loss to follow-up. Participants contribute by allowing access to their medical records for analysis of healthcare contacts and procedures over time. Researchers will measure the number of liver cirrhosis-related outpatient visits and diagnostic tests. The study tracks these healthcare events retrospectively up to two years before significant complications or other endpoints. The overall study duration extends until December 2027.
Actively Recruiting
Researchers are evaluating hypofractionated definitive chemoradiotherapy as a treatment for patients with locally advanced esophageal or gastroesophageal junction GEJ cancer. This study aims to determine if delivering a shorter, more intense course of radiation combined with chemotherapy is feasible and safe, with a focus on understanding treatment-related toxicity, especially radiation-induced lymphopenia. Participants will receive 20 fractions of 2.4 Gy radiation alongside six cycles of carboplatin and paclitaxel chemotherapy over four weeks. This approach is compared to the usual treatment of 28 fractions over 5.5 weeks with the same chemotherapy regimen. After treatment, participants will undergo follow-up according to standard care practices. Throughout the study, researchers will monitor how many patients complete the full course of radiotherapy and chemotherapy. They will also assess the incidence and severity of lymphopenia and other acute toxicities at multiple time points during and after treatment. This includes blood tests and clinical evaluations up to three months post-treatment to ensure safety and gather comprehensive outcome data.
1-10 of 29
1